Allogene Therapeutics Announces Planned CEO Succession
Allogene Therapeutics reveals that current CEO and President Dr. David Chang will transition from his role on June 30, 2026, after eight years of leadership, continuing as a board member. Dr. Zachary Roberts, EVP of Research & Development and Chief Medical Officer since 2023, will succeed him as President and CEO starting July 1, 2026, and join the…